Feb 14, 2023 8:00am EST Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting
Feb 07, 2023 8:05am EST Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
Feb 01, 2023 8:05am EST Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
Jan 25, 2023 8:05am EST Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
Jan 23, 2023 8:05am EST Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational
Jan 04, 2023 8:05am EST Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial
Dec 19, 2022 8:05am EST Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection